Venus Concept Inc (VERO)
0.8899
+0.03 (+3.94%)
USD |
NASDAQ |
May 16, 11:48
Venus Concept Enterprise Value: 102.44M for May 13, 2022
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 13, 2022 | 102.44M |
| May 12, 2022 | 92.44M |
| May 11, 2022 | 90.67M |
| May 10, 2022 | 94.75M |
| May 09, 2022 | 93.99M |
| May 06, 2022 | 97.56M |
| May 05, 2022 | 99.48M |
| May 04, 2022 | 102.81M |
| May 03, 2022 | 99.48M |
| May 02, 2022 | 101.65M |
| April 29, 2022 | 101.02M |
| April 28, 2022 | 111.96M |
| April 27, 2022 | 110.87M |
| April 26, 2022 | 110.05M |
| April 25, 2022 | 113.56M |
| April 22, 2022 | 116.12M |
| April 21, 2022 | 119.96M |
| April 20, 2022 | 123.16M |
| April 19, 2022 | 130.20M |
| April 18, 2022 | 127.64M |
| April 14, 2022 | 130.84M |
| April 13, 2022 | 133.40M |
| April 12, 2022 | 133.40M |
| April 11, 2022 | 134.04M |
| April 08, 2022 | 139.16M |
| Date | Value |
|---|---|
| April 07, 2022 | 135.32M |
| April 06, 2022 | 135.96M |
| April 05, 2022 | 143.00M |
| April 04, 2022 | 148.12M |
| April 01, 2022 | 144.92M |
| March 31, 2022 | 139.16M |
| March 30, 2022 | 138.52M |
| March 29, 2022 | 138.52M |
| March 28, 2022 | 138.52M |
| March 25, 2022 | 135.96M |
| March 24, 2022 | 135.96M |
| March 23, 2022 | 136.58M |
| March 22, 2022 | 136.58M |
| March 21, 2022 | 137.22M |
| March 18, 2022 | 135.94M |
| March 17, 2022 | 135.30M |
| March 16, 2022 | 134.66M |
| March 15, 2022 | 130.18M |
| March 14, 2022 | 130.82M |
| March 11, 2022 | 137.22M |
| March 10, 2022 | 137.86M |
| March 09, 2022 | 142.98M |
| March 08, 2022 | 137.86M |
| March 07, 2022 | 142.98M |
| March 04, 2022 | 144.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
12.45M
Minimum
Dec 24 2018
297.66M
Maximum
Oct 12 2017
131.32M
Average
147.94M
Median
Nov 12 2020
Enterprise Value Benchmarks
| Zymeworks Inc | 20.10M |
| Aurinia Pharmaceuticals Inc | 1.165B |
| Edesa Biotech Inc | 19.60M |
| Lexaria Bioscience Corp | 3.060M |
| Liminal Biosciences Inc | -45.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.333M |
| Revenue (Quarterly) | 32.63M |
| Total Expenses (Quarterly) | 36.70M |
| EPS Diluted (Quarterly) | -0.08 |
| Gross Profit Margin (Quarterly) | 69.98% |
| Profit Margin (Quarterly) | -13.28% |
| Earnings Yield | -47.54% |
| Normalized Earnings Yield | -46.59 |